🔍

TTKHLTCARE - TTK Healthcare

📊 NSE: TTKHLTCARE 🏢 Diversified - Medium / Small 📅 Last Updated: 12/14/2025 14:34

📢 Recent Corporate Announcements

TTK Healthcare: Independent Director N Ramesh Rajan Completes Final Term on Feb 2, 2026

🟡 NEUTRAL ⭐ 3/10

MANAGEMENT 📅 02 Feb 2026, 05:44 PM

TTK Healthcare Limited has announced that Mr. N Ramesh Rajan has completed his second and final term as an Independent Director on February 02, 2026. Consequently, he will cease to be a Director and a member or chairman of various Board Committees effective February 03, 2026. The company has confirmed that the Board and its Committees remain in full compliance with applicable laws following this retirement. This is a routine management transition necessitated by statutory term limits for independent directors under Indian law.

Mr. N Ramesh Rajan completed his second and final term as Independent Director on February 02, 2026.
Cessation of directorship and committee memberships is effective from February 03, 2026.
The company maintains regulatory compliance regarding Board and Committee composition post-retirement.
The disclosure was made under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

💡 This is a routine statutory retirement with no impact on business operations; no immediate action is required from investors.

TTK Healthcare: Independent Director N Ramesh Rajan Completes Tenure on Feb 02, 2026

🟡 NEUTRAL ⭐ 3/10

MANAGEMENT 📅 02 Feb 2026, 05:44 PM

TTK Healthcare Limited has announced that Mr. N Ramesh Rajan has completed his second and final term as an Independent Director on February 02, 2026. Consequently, he will cease to be a Director and Chairman/Member of various Board Committees effective February 03, 2026. The company confirmed that the Board's composition remains in compliance with regulatory requirements despite this retirement. This is a routine transition following the completion of statutory term limits for independent directors.

Mr. N Ramesh Rajan (DIN: 01628318) completed his second and final term as Independent Director
The cessation is effective from the close of business hours on February 02, 2026
Mr. Rajan also steps down as Member and Chairman of various Board Committees
The company maintains compliance with SEBI Listing Regulations regarding Board composition

💡 This is a routine regulatory exit due to term limits and requires no immediate action from investors. Monitor for any new appointments to the board in the coming quarters.

TTK Healthcare Independent Director N Ramesh Rajan Completes Second Term

🟡 NEUTRAL ⭐ 3/10

MANAGEMENT 📅 02 Feb 2026, 05:44 PM

Mr. N Ramesh Rajan has stepped down as a Non-Executive Independent Director of TTK Healthcare Limited effective February 03, 2026. This cessation follows the completion of his second and final term as per statutory requirements. The company has stated that the Board and its various committees remain fully compliant with all applicable laws and regulations post this change. This is a routine transition and does not signal any internal conflict or operational issues.

Completion of second and final term as Independent Director on February 02, 2026.
Effective cessation from the Board and all Committee memberships on February 03, 2026.
Board composition remains in compliance with SEBI Listing Obligations and Disclosure Requirements.

💡 This is a routine regulatory exit; no specific action is needed from shareholders. Monitor for the appointment of a successor to evaluate the board's future expertise.

TTK Healthcare Shareholders Approve Appointment of V Sundaresan as Independent Director

🟡 NEUTRAL ⭐ 4/10

MANAGEMENT 📅 27 Jan 2026, 02:57 PM

TTK Healthcare Limited has successfully passed a special resolution via postal ballot for the appointment of Mr. V Sundaresan as an Independent Director for a five-year term. The resolution received near-unanimous approval from shareholders, with 99.9992% of votes cast in favor. The appointment is effective from December 22, 2025, following a voting process that saw a 75.48% turnout of the total share capital. This move strengthens the company's board governance with a long-term independent appointment.

Mr. V Sundaresan appointed as Independent Director for a 5-year term effective December 22, 2025
Special resolution passed with 99.9992% votes in favor (10,666,158 votes)
Total voter turnout represented 75.48% of the company's total shares with 10,666,239 votes polled
Promoter group and Public Institutions showed near-unanimous support for the appointment
Only 81 votes (0.0008%) were cast against the resolution across all shareholder categories

💡 This is a routine governance update and requires no immediate action from investors. The high level of shareholder consensus indicates strong confidence in the board's leadership choices.

TTK Healthcare Q3 Net Profit Drops 37% to ₹10.53 Cr; Impacted by ₹7.58 Cr Exceptional Item

🔴 NEGATIVE ⭐ 7/10

EARNINGS 📅 22 Jan 2026, 01:20 PM

TTK Healthcare reported a 37% year-on-year decline in net profit for Q3 FY26, falling to ₹10.53 crore from ₹16.73 crore. While revenue remained relatively flat at ₹209.30 crore, the bottom line was severely impacted by a one-time exceptional charge of ₹7.58 crore related to the implementation of new Labour Codes. Segment-wise, the Consumer Products and Medical Devices divisions saw margin pressure, while the Protective Devices division continued to report losses. On a positive note, the Foods and Animal Welfare segments showed improved profitability during the quarter.

Revenue from operations grew marginally by 2.2% YoY to ₹209.30 crore compared to ₹204.74 crore.
Net profit declined 37% YoY to ₹10.53 crore, primarily due to a ₹7.58 crore exceptional charge for labour code adjustments.
Consumer Products segment profit fell sharply to ₹2.25 crore from ₹6.45 crore in the previous year's quarter.
Protective Devices segment recorded a loss of ₹1.10 crore, widening from a loss of ₹0.31 crore YoY.
The company reconstituted its board committees following the retirement of Independent Director Mr. N Ramesh Rajan.

💡 Investors should monitor the recovery in the Consumer Products segment and the narrowing of losses in the Protective Devices division. While the profit dip is largely due to a non-recurring regulatory charge, the underlying operational weakness in core segments warrants a cautious approach.

TTK Healthcare Q3 Net Profit Drops 37% to ₹10.53 Cr; Impacted by ₹7.58 Cr Exceptional Item

🔴 NEGATIVE ⭐ 7/10

EARNINGS 📅 22 Jan 2026, 01:18 PM

TTK Healthcare reported a 37% year-on-year decline in net profit for Q3 FY26, falling to ₹10.53 crore from ₹16.73 crore. The bottom line was significantly impacted by a one-time exceptional charge of ₹7.58 crore related to the implementation of new Labour Codes affecting gratuity and leave provisions. While revenue from operations remained relatively flat at ₹209.30 crore, the Protective Devices segment continued to struggle, reporting a loss of ₹1.10 crore. Conversely, the Animal Welfare and Medical Devices segments showed healthy revenue growth during the quarter.

Net Profit for Q3 FY26 fell 37% YoY to ₹1,053.26 lakhs compared to ₹1,673.24 lakhs in the previous year.
Revenue from operations grew marginally by 2.2% YoY to ₹20,929.89 lakhs.
Recognized a net exceptional charge of ₹757.87 lakhs due to the incremental impact of new Labour Codes on employee benefits.
Protective Devices segment reported a loss of ₹110.23 lakhs, continuing a trend of underperformance.
Animal Welfare and Medical Devices segments saw revenue growth of 15.5% and 19.1% YoY respectively.

💡 Investors should monitor the recovery in the Protective Devices segment and the stabilization of margins following the one-time labour code adjustments. The stock may face short-term pressure due to the sharp decline in quarterly profitability.

TTK Healthcare Q3 Net Profit Falls 37% to ₹10.53 Cr Due to ₹7.58 Cr Exceptional Labour Code Charge

🔴 NEGATIVE ⭐ 7/10

EARNINGS 📅 22 Jan 2026, 01:17 PM

TTK Healthcare reported a marginal 2.2% YoY growth in revenue from operations to ₹209.30 crore for Q3 FY26. However, Net Profit declined significantly by 37% YoY to ₹10.53 crore, primarily impacted by a one-time exceptional charge of ₹7.58 crore related to the implementation of new Labour Codes. While the Foods and Animal Welfare segments showed improved profitability, the core Consumer Products and Medical Devices divisions faced margin pressure, and the Protective Devices segment continued to report losses.

Revenue from operations grew slightly to ₹209.30 crore in Q3 FY26 from ₹204.74 crore in Q3 FY25.
Net Profit dropped 37% YoY to ₹10.53 crore, down from ₹16.73 crore in the same quarter last year.
Recognized a net exceptional charge of ₹757.87 lakhs for incremental Gratuity and Long-term Compensated Absences following new Labour Code notifications.
Consumer Products segment profit slumped to ₹2.25 crore from ₹6.45 crore YoY, indicating significant margin pressure.
Foods segment performed strongly with profit rising to ₹3.40 crore compared to ₹1.43 crore in the previous year's quarter.

💡 The profit decline is largely attributed to a non-recurring regulatory accounting charge; however, the sharp drop in Consumer Products margins is a fundamental concern. Investors should monitor if the growth in the Foods segment can offset the volatility in the Protective and Consumer product divisions.

TTK Healthcare Files Quarterly Compliance Certificate Under SEBI Regulations

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 02 Jan 2026, 02:39 PM

TTK Healthcare Limited has submitted its quarterly compliance certificate for the period ended December 31, 2025, in accordance with SEBI (Depositories and Participants) Regulations. The filing confirms that the company's Registrar and Share Transfer Agent, Data Software Research Co. Pvt. Ltd., processed all dematerialization requests within the mandated 15-day timeframe. This process involves the cancellation of physical share certificates and updating the depository as the registered owner. This is a standard regulatory disclosure ensuring the integrity of the shareholding records.

Compliance certificate submitted for the quarter ended December 31, 2025.
Adherence to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018.
Dematerialization requests were processed and certificates cancelled within 15 days.
Verification provided by Registrar and Share Transfer Agent, Data Software Research Co. Pvt. Ltd.

💡 No action is required from investors as this is a routine administrative filing with no impact on the company's financial performance or operations.

TTK Healthcare Transmits 7.73 Lakh Shares to Legal Heirs of Deceased Promoters

🟡 NEUTRAL ⭐ 4/10

MANAGEMENT 📅 29 Dec 2025, 05:47 PM

TTK Healthcare has announced the transmission of equity shares following the demise of Promoter Late Thiruvallur Thattai Jagannathan and Promoter Group member Late Thiruvallur Thattai Venkatesh. A total of 7,59,298 shares from the deceased promoter were distributed among three legal heirs, while 14,000 shares were transferred to a fourth heir. Consequently, Ms. Sarayu Thiruvallur Thattai has been newly classified as part of the Promoter Group. These changes will be reflected in the shareholding pattern for the quarter ending December 31, 2025.

Transmission of 7,59,298 shares from Late Thiruvallur Thattai Jagannathan to three heirs.
Transmission of 14,000 shares from Late Thiruvallur Thattai Venkatesh to Ms. Sarayu Thiruvallur Thattai.
Ms. Sarayu Thiruvallur Thattai (minor) is now officially classified under the Promoter Group.
Late T.T. Jagannathan and Late T.T. Venkatesh cease to be part of the Promoter/Promoter Group.
The update ensures compliance with SEBI LODR Regulations 30 and 31A.

💡 This is a routine administrative update regarding the inheritance of shares and does not affect the company's business operations. Investors should treat this as a neutral regulatory filing with no immediate impact on stock valuation.

TTK Healthcare Announces Transmission of 7.73 Lakh Shares to Promoter Heirs

🟡 NEUTRAL ⭐ 4/10

ROUTINE 📅 29 Dec 2025, 05:44 PM

TTK Healthcare has processed the transmission of 7,59,298 equity shares previously held by the late promoter, Thiruvallur Thattai Jagannathan, to three legal heirs. Additionally, 14,000 shares from the late promoter group member Thiruvallur Thattai Venkatesh were transmitted to Sarayu Thiruvallur Thattai. As a result, Sarayu Thiruvallur Thattai is now officially classified as part of the Promoter Group. These administrative changes in the shareholding structure will be reflected in the filing for the quarter ending December 31, 2025.

Transmission of 7,59,298 shares from late promoter T.T. Jagannathan to three legal heirs.
Mukund T.T. and Tiruvallur T. Lakshman each received 2,53,099 shares.
Sarayu T.T. received a total of 2,67,100 shares and is newly classified under the Promoter Group.
Late T.T. Jagannathan and Late T.T. Venkatesh ceased to be part of the Promoter and Promoter Group respectively.
The total promoter group holding remains unchanged despite the internal redistribution.

💡 This is a routine administrative update regarding the inheritance of shares within the promoter family. Investors should note that this does not impact the company's operations or overall promoter control.

TTK Healthcare to Close Trading Window from Jan 1, 2026, for Q3 Results

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 26 Dec 2025, 03:57 PM

TTK Healthcare Limited has announced the closure of its trading window for all designated persons and their immediate relatives starting January 1, 2026. This action is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, ahead of the company's third-quarter financial results. The window will remain closed until 48 hours after the unaudited financial results for the quarter ending December 31, 2025, are declared. This is a standard regulatory procedure and does not indicate any fundamental change in the company's operations.

Trading window closure begins on January 1, 2026, for the Q3 FY26 reporting period.
Closure applies to all Designated Persons and their immediate relatives as per SEBI regulations.
The window will reopen 48 hours after the declaration of the Unaudited Financial Results for the quarter ending December 31, 2025.
The specific date for the Board Meeting to approve these results will be announced at a later date.

💡 This is a routine regulatory filing. Investors should monitor the upcoming announcement of the Board Meeting date for the actual Q3 financial performance results.

TTK Healthcare Seeks Shareholder Approval for Appointment of Independent Director for 5-Year Term

🟡 NEUTRAL ⭐ 4/10

MANAGEMENT 📅 24 Dec 2025, 04:09 PM

TTK Healthcare has issued a postal ballot notice to seek shareholder approval via special resolution for the appointment of Mr. V Sundaresan as an Independent Director. The proposed term is for five years, effective from December 22, 2025, through December 21, 2030. Notably, the resolution also seeks approval for his continuation in the role even after he reaches the age of 75 during his tenure. Shareholders as of the cut-off date of December 19, 2025, are eligible to participate in the e-voting process which concludes on January 24, 2026.

Appointment of Mr. V Sundaresan as an Independent Director for a 5-year term starting Dec 22, 2025
Special Resolution required for appointment and continuation of directorship beyond 75 years of age
E-voting period is scheduled from Dec 26, 2025 (9:00 AM) to Jan 24, 2026 (5:00 PM)
The cut-off date for determining shareholder eligibility for voting was Dec 19, 2025

💡 Investors should review the appointee's profile in the explanatory statement to ensure the board maintains strong independent oversight. No immediate trading action is required as this is a routine governance matter.

TTK Healthcare Appoints Former TTK Prestige CFO V Sundaresan as Independent Director

🟢 POSITIVE ⭐ 6/10

MANAGEMENT 📅 22 Dec 2025, 01:21 PM

TTK Healthcare has appointed Mr. V Sundaresan as an Additional Independent Director for a five-year term effective December 22, 2025. Mr. Sundaresan is a veteran professional with nearly 40 years of experience, including a 30-year tenure within the TTK Group where he served as the CFO of TTK Prestige Ltd. The appointment is subject to shareholder approval via a postal ballot process, with voting concluding on January 24, 2026. His deep expertise in corporate finance, audit, and internal controls is expected to enhance the company's governance framework.

Appointment of Mr. V Sundaresan as Additional Independent Director for a 5-year term starting December 22, 2025
Appointee previously served as CFO of TTK Prestige Ltd and has nearly 40 years of leadership experience in finance and audit
Shareholder approval to be sought through Postal Ballot with remote e-voting from December 26, 2025, to January 24, 2026
Final results of the postal ballot and director appointment confirmation expected by January 28, 2026

💡 Investors should view this as a positive governance move, bringing in a seasoned financial expert familiar with the group's operations. No immediate portfolio changes are required.

TTK Healthcare Appoints Former TTK Prestige CFO V Sundaresan as Independent Director

🟢 POSITIVE ⭐ 6/10

MANAGEMENT 📅 22 Dec 2025, 01:18 PM

TTK Healthcare has appointed Mr. V Sundaresan as an Additional Independent Director for a five-year term effective December 22, 2025. Mr. Sundaresan brings nearly 40 years of experience in finance and audit, having previously served as the CFO of TTK Prestige for nearly three decades. The appointment is subject to shareholder approval via a postal ballot process ending January 24, 2026. This move strengthens the board's financial oversight and governance, leveraging his deep familiarity with the TTK Group's operations.

Appointment of Mr. V Sundaresan as Additional Independent Director for a 5-year term starting Dec 22, 2025.
The appointee has nearly 40 years of experience and served as CFO of group company TTK Prestige for 30 years.
Shareholder approval to be sought via Postal Ballot with e-voting concluding on January 24, 2026.
Mr. Sundaresan is a Fellow Member of the ICAI with extensive expertise in corporate finance, audit, and ERP implementation.

💡 The appointment of a seasoned financial expert from the group's ecosystem is a positive step for corporate governance. No immediate action is required other than noting the strengthening of the board's oversight capabilities.

TTK Healthcare Appoints Former TTK Prestige CFO V Sundaresan as Independent Director

🟢 POSITIVE ⭐ 6/10

MANAGEMENT 📅 22 Dec 2025, 01:16 PM

TTK Healthcare has appointed Mr. V Sundaresan as an Additional Independent Director for a five-year term effective December 22, 2025. Mr. Sundaresan is a seasoned professional with nearly 40 years of experience in finance and audit, including a 30-year tenure at TTK Prestige where he retired as CFO in 2020. The appointment is subject to shareholder approval via a postal ballot process scheduled to conclude on January 24, 2026. This appointment is expected to strengthen the company's financial governance and strategic oversight.

Appointment of Mr. V Sundaresan as Additional Independent Director for a 5-year term starting Dec 22, 2025
Appointee brings 40 years of leadership experience and previously served as CFO of TTK Prestige Ltd
Shareholder approval to be sought through Postal Ballot with e-voting from Dec 26, 2025, to Jan 24, 2026
The board meeting was held on December 22, 2025, and concluded within 15 minutes

💡 Investors should view this as a positive governance move given the appointee's deep financial expertise and familiarity with the TTK Group. No immediate portfolio action is required.

View All TTKHLTCARE Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Overall revenue grew 6.5% YoY to INR 801.5 Cr in FY2025 from INR 752.8 Cr in FY2024. Growth was reported across all divisions including Animal Welfare, Consumer Products, Food Products, Protective and Medical Devices. Q1 FY2026 revenue stood at INR 226.4 Cr.

Geographic Revenue Split

Not disclosed in available documents; however, the company maintains a wide distribution network across India.

Profitability Margins

Operating profit margins remained low at 4.5% in FY2025 (compared to 4.4% in FY2023) due to the distribution-heavy nature of the business. Margins significantly declined to 1.2% in Q1 FY2026 from 5.0% in Q1 FY2024, primarily due to higher sales promotion and branding expenses.

EBITDA Margin

EBITDA margin (OPBDIT/OI) was 4.5% in FY2025, up from 3.6% in FY2022 (excluding human pharma). The decline to 1.2% in Q1 FY2026 reflects a 380 bps YoY contraction due to competitive intensity.

Capital Expenditure

The company has planned maintenance capital expenditure of INR 10.0-12.0 Cr per annum for the FY2026-FY2028 period, to be funded through internal accruals.

Credit Rating & Borrowing

Long-term rating is [ICRA]A+ (Stable) as of September 2025. Short-term rating is [ICRA]A1+. Borrowing costs are minimal as the company is net-debt negative with only INR 22.6 Cr in working capital borrowings against INR 927.0 Cr in cash as of June 2025.

⚙️ Operational Drivers

Raw Materials

Not specifically disclosed, but the company operates an outsourcing model for most products except for Food Products, Medical, and Protective devices.

Capacity Expansion

Currently operates 6 manufacturing units. No major capacity expansion plans were disclosed beyond maintenance capex of INR 10-12 Cr per annum.

Raw Material Costs

Not disclosed as a specific percentage of revenue; however, the company's ability to pass on cost inflation is noted as a risk mitigation factor.

Logistics & Distribution

Not disclosed as a specific percentage; however, the 'distribution nature' of the business is cited as the primary reason for low operating margins (4.5%).

📈 Strategic Growth

Expected Growth Rate

6.50%

Growth Strategy

Growth will be driven by scaling up revenues to gain operating leverage, cost-optimization measures, and the potential deployment of the INR 802.8 Cr cash surplus from the human pharma divestment for future expansion or acquisitions.

Products & Services

Contraceptives, Woodward's Gripe Water, cosmetics, medical devices, home-care products, and ready-to-fry papads.

Brand Portfolio

TTK, Woodward's, TTK Healthcare.

Market Share & Ranking

Maintains a 'healthy market share' in key segments like contraceptives and gripe water, though specific percentages are not disclosed.

Strategic Alliances

Holds a 26% equity stake in BSV Pharma Private Limited following the divestment of its human pharma division.

🌍 External Factors

Industry Trends

The FMCG industry is shifting toward organically grown input materials, carbon neutrality, and stricter regulations regarding the usage of plastics in packaging.

Competitive Landscape

Faces intense competition from both large organized players and unorganized local manufacturers across all product segments.

Competitive Moat

Durable advantages include strong brand equity in niche categories (Gripe Water, Contraceptives), a well-entrenched pan-India distribution network, and the reputation of the TT Krishnamachari Group.

Consumer Behavior

Increasing health consciousness among consumers is impacting demand for certain traditional product categories.

⚖️ Regulatory & Governance

Industry Regulations

Subject to manufacturing standards for medical and protective devices, and environmental regulations for FMCG waste management.

Environmental Compliance

Exposed to evolving environmental norms regarding manufacturing residual discharge and restrictions on plastic packaging usage.

Legal Contingencies

No significant pending court cases or case values were disclosed in the auditor's report for FY2025.

⚠️ Risk Analysis

Key Uncertainties

The primary uncertainty is the lack of clarity regarding the deployment of the INR 802.8 Cr cash surplus, which could significantly impact the company's future scale and rating.